Companion Diagnostics (CDx) and Clinical Trial Support
Exosome Diagnostics provides a comprehensive approach to CDx development and clinical trial support.
After marker identification, biomarkers and/or gene signatures enter our development process to become targeted assays. The newly identified biomarkers are developed into a Laboratory Developed Test (LDT) that will be run in Exosome Diagnostic’s CLIA and CAP accredited laboratory.
Drug Development
Diagnostic Development
Tissue & Additional Services
Exosome Diagnostics also offers additional biomarker testing services that are not exosome based, such as soluble protein and cell free DNA (cfDNA) analysis. We can utilize tissue, FFPE, whole blood, cell culture materials or other sample types for protein and nucleic acid analysis.